TACE Combined With Donafenib and Tislelizumab in Unresectable Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma Interventions: Drug: Transarterial chemoembolization combined with Donafenib and Tislelizumab Sponsors: Guangxi Medical University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials